GlassScriptPhysician profile
Anna Marie Davis
NPI 1689228975
$649.27
in general payments reported to CMS, 2019-2025
11 companies · $75.37 in 2025
The $75.37 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.15 · 2022: $152 · 2023: $241 · 2024: $169 · 2025: $75.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $155.72 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Eisai INC. | $125.00 | 2022 | |
| Exact Sciences Corporation | $86.77 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $78.30 | 2021-2025 | Airsupra |
| Amgen INC. | $52.08 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $49.26 | 2023 | |
| Boston Scientific Corporation | $27.90 | 2025 | Wavewriter Alpha Prime 16 |
| Corium, LLC | $27.36 | 2022 | |
| Pfizer INC. | $18.48 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.14 | 2025 | Caplyta |
| Novo Nordisk INC | $13.26 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.